Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Jun 16

New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress

  • 16th June 2018
  • News

Exiris presents data on novel cytotoxic peptide-drug conjugates for tumor targeted therapy, generated in collaboration with the University of Bielefeld and Italfarmaco within the Horizon 2020 MAGICBULLET project. Two lectures and two posters were presented on this topic.

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • E-Mail

Comments are closed.

Latest News

  • Interview with Paola Gallinari on “Osservatorio medico-scientifico”
  • Exiris @ RaiNews24
  • Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019
  • Exiris receives European Union research grant for the ETN MAGICBULLET RELOADED project
  • New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018
  • New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress
  • Exiris is awarded a grant from Regione Lazio LIFE 2020
  • Exiris files patent application on novel cancer therapeutic antibodies
  • New data presented at the 7th Annual World ADC Berlin 2017
  • Exiris @ Presa Diretta
© 2016 Exiris Srl · P.IVA 10897561006